Improvement of renal function after transcatheter aortic valve replacement in patients with chronic kidney disease

Michel V. Lemes da Silva1,2, Antonio C. B. Nunes Filho1,*, Vitor E. E. Rosa1,2, Adriano Caixeta1, Pedro A. Lemos Neto1, Henrique B. Ribeiro2, Breno O. Almeida1, José Mariani, Jr1, Carlos M. Campos2,3, Alexandre A. C. Abizaid4, José A. Mangione5, Roney O. Sampaio2, Paulo Caramori5, Rogério Sarmento-Leite6, Flávio Tarasoutchi1,2, Marcelo Franken1, Faíbio S. de Brito, Jr2

1 Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil, 2 Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil, 3 Department of Cardiology, Instituto Prevent Senior, Sao Paulo, Brazil, 4 Department of Interventional Cardiology, Hospital Beneficiência Portuguesa, Sao Paulo, Brazil, 5 Department of Interventional Cardiology, Hospital São Lucas – PUCRS, Porto Alegre, Brazil, 6 Department of Interventional Cardiology, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil

* antonio.filho@einstein.br

Abstract

Background
Chronic kidney disease is commonly found in patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) and has marked impact in their prognosis. It has been shown however that TAVR may improve renal function by alleviating the hemodynamic barrier imposed by AS. Nevertheless, the predictors of and clinical consequences of renal function improvement are not well established.

Our aim was to assess the predictors of improvement of renal function after TAVR.

Methods
The present work is an analysis of the Brazilian Registry of TAVR, a national non-randomized prospective study with 22 Brazilian centers. Patients with baseline renal dysfunction (estimated glomerular filtration rate [eGFR] < 60mL/min/1.73m²) were stratified according to renal function after TAVR: increase >10% in eGFR were classified as TAVR induced renal function improvement (TIRFI); decrease >10% in eGFR were classified as acute kidney injury (AKI) and stable renal function (neither criteria).

Results
A total of 819 consecutive patients with symptomatic severe AS were included. Of these, baseline renal dysfunction (estimated glomerular filtration rate [eGFR] < 60mL/min/1.73m²) was present in 577 (70%) patients. Considering variance in renal function between baseline and at discharge after TAVR procedure, TIRFI was seen in 197 (34.1%) patients, AKI in 203 (35.2%), and stable renal function in 177 (30.7%).
The independent predictors of TIRFI were: absence of coronary artery disease (OR: 0.69; 95% CI 0.48–0.98; P = 0.039) and lower baseline eGFR (OR: 0.98; 95% CI 0.97–1.00; P = 0.039). There was no significant difference in 30-day and 1-year all-cause mortality between patients with stable renal function or TIRFI. Nonetheless, individuals that had AKI after TAVR presented higher mortality compared with TIRFI and stable renal function groups (29.3% vs. 15.4% vs. 9.5%, respectively; p < 0.001).

Conclusions
TIRFI was frequently found among baseline impaired renal function individuals but was not associated with improved 1-year outcomes.

Introduction
Transcatheter aortic valve replacement (TAVR) is a well-established treatment for patients who cannot undergo surgery and those with intermediate to high surgical risk with symptomatic severe aortic stenosis [1–6]. More recently, TAVR indications have also been expanded for patients at low surgical risk, as well as for dysfunctional bioprosthesis [7, 8].

Among the patients currently undergoing TAVR, a high prevalence of non-cardiac comorbidities are frequently observed, including chronic kidney disease (CKD) that ranged from 52% to 72% in prior studies [9–11]. Moreover, renal function impairment at baseline also denotes worse clinical outcomes following TAVR, including higher mortality rates [10–14], particularly when acute kidney injury (AKI) after TAVR ensues [9, 15–17]. Of note, some patients may also experience renal function improvement after TAVR, regardless of the baseline renal condition, and also despite the various procedural factors that could jeopardize renal function such as hypotension during rapid pacing, use of iodinated contrast media, bleeding and athero-emboli. Yet, such adverse effects may be mitigated by the beneficial effects after the AS relief leading to improvement in cardiac output and better renal perfusion [9, 15, 16].

However, there is divergence in recent studies about the effects of the improvement in renal function after TAVR regarding better outcomes, and its real role still needs more investigation [9, 16].

This study aims to determine the predictors and prognosis of renal function improvement after TAVR using data from the Brazilian TAVR Registry.

Methods
Study population
From January 2008 to January 2015, 819 consecutive patients with symptomatic severe AS underwent TAVR and were included in the Brazilian TAVR Registry [18], which is a non-randomized prospective registry, including 22 Brazilian centers. Patients with baseline impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m², were selected. eGFR was calculated using Chronic Kidney Disease Epidemiology formula (CKD-EPI) [19], expressed by GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)−1.209 * 0.993^Age * 1.018 [if female] * 1.159 [if black], which Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. Also, 25 patients who died within the first 24 hours and 60 patients with missing data (4 patients without baseline eGFR, 55
patients without eGFR at discharge and 1 patient without eGFR at both moments) were excluded, remaining 577 patients who were included in the study (Fig 1). The study protocol was conducted in accordance with the Declaration of Helsinki and was approved by each institution’s ethics committee under protocol number 05676012.4.1001.00701, and all participants had provided informed consent. The follow-up was performed by phone calls at 1 month, 1 year and then annually.

**Procedure**

Patients with symptomatic severe AS (aortic valve area < 1.0 cm² and mean aortic valve gradient of ≥ 40 mmHg or peak aortic jet velocity of ≥ 4.0 m/s) were submitted to TAVR with self-expandable CoreValve prosthesis (Medtronic, Minneapolis, MN, USA), balloon-expandable Sapien XT prosthesis (Edwards Lifesciences, Irvine, CA, USA) or balloon-expandable Inovare prosthesis (Braile Biomédica, São José do Rio Preto, SP, Brazil). TAVR procedures were performed according to standard techniques. Aspirin (100 mg/day) and clopidogrel (300 mg loading dose and 75 mg/day) were administered to patients for at least 1 month. The preferable access was the transfemoral approach. When it was not feasible, transapical or transarterial approaches (transsubclavian, direct transaortic, transapical or transcarotid) were used according to the preference of the Heart Team. Clinical, procedural and echocardiographic data were prospectively gathered into a pre-set TAVR database. Outcomes were defined according to the Valve Academic Research Consortium 2 (VARC-2) [20]. All outcomes and adverse events were adjudicated by an independent committee.

**Group definition**

Serum creatinine was collected at baseline and daily after the procedure until discharge. The first creatinine (baseline) was collected on the day or the day before TAVR procedure. The second creatinine used to calculate variation on renal function was at discharge. The median length of stay was 7 days (1–368) and the mean hospitalization period was 13 days. The CKD-EPI formula was used to calculate the eGFR at baseline and at discharge after TAVR procedure. Patients were categorized according to renal function variation after TAVR: increase > 10% in eGFR were classified as TAVR induced renal function improvement (TIRFI); decrease > 10% in eGFR were classified as AKI; and stable renal function (neither criteria) [9, 15].

**Statistical analysis**

Continuous variables were reported as mean ± standard deviation, and the comparison between the 3 groups was performed using the ANOVA test, except for contrast media volume which Kruskal-Wallis test was used. Post-hoc analysis was performed using Tukey’s test. Categorical variables were reported as frequencies and percentages, and were compared using the Pearson chi-square test. Cox proportional hazards models were used to test the impact of TIRFI and AKI on all-cause death and cardiovascular mortality, and the models were adjusted for age, male sex, New York Heart Association functional class III/IV, diabetes, hypertension, chronic obstructive lung disease, pulmonary hypertension, coronary artery disease, peripheral vascular disease, previous coronary artery bypass grafting, STS score, baseline eGFR, use of diuretics, Angiotensin-converting enzyme inhibitors or Angiotensin II receptor blockers, beta-blockers, statin, left ventricular ejection fraction, aortic valve area, mean aortic valve gradient, contrast media volume, procedural access (except transfemoral), Inovare prosthesis, AKI and TIRFI, myocardial infarction, stroke/transient ischemic attack, major or life-threatening bleeding, major vascular complication, new left bundle branch block, atrioventricular
block, valve malpositioning and new pacemaker. Kaplan-Meier survival curves were created comparing TIRFI, stable renal function and AKI groups and the outcomes were compared using a log-rank test. A stepwise logistic regression analysis including all variables with a P value < 0.2 in the univariate analysis was used to identify the predictors of TIRFI and AKI after the procedure until discharge. The models were adjusted for age, male sex, New York Heart Association functional class III/IV, diabetes, hypertension, chronic obstructive lung disease, pulmonary hypertension, coronary artery disease, peripheral vascular disease, previous coronary artery bypass grafting, STS score, baseline eGFR, use of diuretics, Angiotensin-converting enzyme inhibitors or Angiotensin II receptor blockers, beta-blockers, statin, left ventricular ejection fraction, aortic valve area, mean aortic valve gradient, contrast media volume, procedural access (except transfemoral), Inovare prosthesis. All statistical tests were 2-sided, and the criteria for statistical significance was P < 0.05. All statistical analyses were performed using SPSS statistical software version 20.0 (IBM, Armonk, New York, USA).

Results
Baseline clinical characteristics
Baseline characteristics of the study population are presented in Table 1. A total of 577 (70%) patients had CKD and were the population of the present study. The overall median length of stay was 7 days (1–368) and the mean hospitalization period was 13 days. After TAVR, 197 (34.1%) patients had TIRFI, 177 (30.7%) maintained stable renal function and 203 (35.2%) had AKI. The overall mean age among CKD patients was 81.3 ± 6.8 years, 56.2% were male, 31.7% had diabetes, 74.5% had hypertension and the mean baseline eGFR was 39.1 ± 12.2 ml/min/1.73m². The mean STS score was 10.6 ± 7.9% and the preferable access site was transfemoral.
Comparing baseline characteristics between the 3 groups, the mean eGFR was 37.3 ± 12.5 ml/min/1.73m² in the TIRFI group, 39.6 ± 11.7 ml/min/1.73m² in the stable renal function group and 40.2 ± 12.3 ml/min/1.73m² in the AKI group, with significant statistical difference between the 3 groups (P = 0.043). This difference was related to TIRFI and AKI.

Table 1. Baseline and procedural characteristics of the study population.

| Clinical data | TIRFI Group (n = 197) | Stable Renal Function Group (n = 177) | AKI Group (n = 203) | Overall (n = 577) | P value * |
|---------------|-----------------------|----------------------------------------|---------------------|-------------------|-----------|
| Age, years    | 81.3 ± 7.1            | 81.7 ± 7.2                             | 82.6 ± 6.2          | 81.3 ± 6.8        | 0.14      |
| Male sex      | 105 (53.3)            | 111 (62.7)                             | 108 (53.2)          | 324 (56.2)        | 0.10      |
| NYHA class III/IV | 166 (84.3) | 146 (82.5)                             | 169 (83.3)          | 481 (83.4)        | 0.89      |
| Diabetes      | 55 (27.9)             | 59 (33.3)                              | 69 (34.0)           | 183 (31.7)        | 0.36      |
| Hypertension  | 149 (75.6)            | 117 (66.1)                             | 164 (80.8)          | 430 (74.5)        | 0.004b    |
| COPD          | 38 (19.3)             | 36 (20.3)                              | 37 (18.8)           | 111 (19.2)        | 0.87      |
| Pulmonary hypertension | 41 (20.8) | 50 (22.8)                             | 47 (23.2)           | 138 (23.9)        | 0.23      |
| CAD           | 110 (55.8)            | 118 (66.7)                             | 123 (60.6)          | 351 (60.8)        | 0.10      |
| Peripheral vascular disease | 35 (17.8) | 26 (14.7)                              | 35 (17.2)           | 96 (16.6)         | 0.69      |
| Previous CABG | 40 (20.3)            | 44 (24.9)                              | 36 (17.7)           | 120 (20.8)        | 0.22      |
| STS score, %  | 10.9 ± 8.4            | 10.2 ± 7.2                             | 10.6 ± 8.1          | 10.6 ± 7.9        | 0.67      |
| eGFR, mL/min/1.73m² | 37.3 ± 12.5 | 39.6 ± 11.7                          | 40.2 ± 12.3         | 39.1 ± 12.2       | 0.043c    |
| Diuretics     | 130 (66.0)            | 105 (59.3)                             | 134 (66.0)          | 369 (64.0)        | 0.30      |
| ACE inhibitors or ARB | 109 (55.3) | 80 (45.2)                            | 108 (53.2)          | 297 (51.5)        | 0.12      |
| Beta-blockers | 77 (39.1)             | 68 (38.4)                              | 75 (36.9)           | 220 (38.1)        | 0.90      |
| Statin        | 117 (59.4)            | 101 (57.1)                             | 128 (63.1)          | 346 (60.0)        | 0.48      |

Echocardiographic data:

| LVEF, %        | 56.8 ± 15.5            | 57.2 ± 16.0                             | 58.4 ± 15.3          | 57.5 ± 15.6        | 0.54      |
| Mean transaortic gradient, mmHg | 49.8 ± 16.5 | 46.5 ± 15.9                          | 48.1 ± 15.8          | 48.2 ± 16.1        | 0.15      |
| AVA, cm²      | 0.68 ± 0.22            | 0.66 ± 0.17                             | 0.66 ± 0.17          | 0.67 ± 0.19        | 0.55      |

Procedural data:

| Access site | 0.12 |
| Transfemoral approach | 188 (95.4) | 167 (94.4) | 184 (90.6) | 539 (93.4) | 0.12      |
| Other        | 9 (4.6)     | 10 (5.6)    | 19 (9.4)   | 38 (6.6)   | 0.80      |
| Prosthesis type | 0.80      |
| Corevalve    | 147 (74.6)                      | 128 (72.3)                         | 151 (74.4)          | 426 (73.8) | 0.80      |
| Sapien XT    | 46 (23.4)     | 43 (24.3)   | 44 (21.6)  | 133 (23.1) | 0.80      |
| Inovare      | 4 (2.0)      | 6 (3.4)     | 8 (3.9)    | 18 (3.1)   | 0.80      |
| Contrast media volume, mL | 188 ± 120 | 186 ± 101 | 181 ± 91 | 185 ± 105 | 0.86      |
| Period of TAVR procedure | 0.15 |
| T1 (2008–2010) | 35 (17.8) | 23 (13.0) | 42 (20.7) | 100 (17.3) | 0.15      |
| T2 (2011–2013) | 112 (56.9) | 118 (66.7) | 122 (60.1) | 352 (61.0) | 0.15      |
| T3 (2014–2015) | 50 (25.4) | 36 (20.3) | 39 (19.2) | 125 (21.7) | 0.15      |

Values are n (%) or mean ± SD.
* Represents significant statistical difference (P<0.05) between TIRF, stable and AKI groups.
* Significant difference (P<0.05) between stable and AKI groups.
* Significant difference (P<0.05) between TIRFI and AKI groups.
Abbreviations: ACE, angiotensin-converting enzyme; AKI, acute kidney injury; ARB, angiotensin receptor blocker; AVA, aortic valve area; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; T, tertile; TIRFI, TAVR induced renal function improvement.

https://doi.org/10.1371/journal.pone.0251066.t001
groups (post-hoc analysis, P = 0.044). Also, hypertension was present among 75.6% patients in TIRFI group, 66.1% in stable renal function group and 80.8% in AKI group, with significant difference between the 3 groups (P = 0.004). This difference was related to stable renal function and AKI groups (post-hoc analysis, P = 0.003). There was no difference related to contrast media volume and other baseline clinical, echocardiographic and procedural characteristics between the 3 groups. In order to evaluate the impact of the extended period of enrollment, we divided our study population into tertiles according to the year they underwent TAVR: 100 (17.3%) patients were submitted to TAVR from 2008 to 2010 (T1), 352 (61.0%) patients from 2011 to 2013 (T2), and 125 (21.7%) from 2014 to 2015 (T3), with no statistical differences between the 3 tertiles (p = 0.15).

**Procedural and clinical outcomes**

Procedural and clinical outcomes are described in Table 2. The occurrence of valve malpositioning was higher in the AKI group compared with TIRFI and stable renal function groups (8.4% vs. 2.0% vs. 2.8%, respectively; P = 0.004). Also, major or life-threatening bleeding was higher in AKI group (20.2% vs. 6.7% vs. 6.3%, respectively; P < 0.001) as well as major vascular complication (10.5% vs. 3.6% vs. 4.0%, respectively; P = 0.006).

**Impact of TIRFI and AKI on short-term outcomes**

At 30 days, patients in AKI group had higher rates of all-cause mortality compared with TIRFI and stable renal function groups (13.0% vs. 2.0% vs. 1.2%, respectively; P < 0.001), and also had higher rates of cardiovascular death (10.6% vs. 1.5% vs. 0.6%, respectively; P < 0.001). There was no significant difference regarding all stroke/transient ischemic attack and myocardial infarction and there was no significant difference in outcomes between TIRFI and stable renal function groups.

**Follow-up at 1 year and loss of follow-up**

Of the 577 patients included in our study, 157 (27.2%) patients lost follow-up or did not complete 1 year of follow-up until the time for data collection for the Brazilian TAVR Registry. However, the median follow-up of the patients included in the present study was 385 [162–742] days. Data comparing the baseline characteristics of the patients with loss of follow-up and those with complete 1-year follow-up are shown as supplemental data (S1 Table).

**Impact of TIRFI and AKI on long-term outcomes**

At 1 year, AKI group remained with higher rates of all-cause mortality compared with TIRFI and stable renal function groups (29.3% vs. 15.4% vs. 9.5%, respectively; P < 0.001), and had higher rates of cardiovascular death (21.0% vs. 6.0% vs. 4.5%, respectively; P < 0.001). There was still no difference regarding stroke/transient ischemic attack and myocardial infarction and there was no significant difference in outcomes between TIRFI and stable renal function groups. Kapplan-Meier curves for 1-year all-cause mortality are represented in Fig 2.

**Predictors of TIRFI and AKI**

Multivariate analysis of TIRFI and AKI are shown in Tables 3 and 4, respectively. The absence of coronary artery disease was an independent predictor of TIRFI (OR: 0.69; 95% CI 0.48–0.98; P = 0.039) as well as lower baseline eGFR (OR: 0.98; 95% CI 0.97–1.00; P = 0.008). Otherwise, independent predictors of AKI were age (HR: 1.03; 95% CI, 1.00–1.05; P = 0.033), hypertension (HR: 1.69; 95% CI, 1.11–2.57; P = 0.014), non-transfemoral access sites (HR: 2.07; 95%
The multivariable analysis of TIRFI and AKI including the procedure complications after TAVR in the model are shown in S2 and S3 Tables.

Table 2. Procedural, 30-day and 1-year outcomes.

|                     | TIRFI Group | Stable Renal Function Group | AKI Group | P value * |
|---------------------|-------------|-----------------------------|-----------|-----------|
|                     | (n = 197)   | (n = 177)                   | (n = 203) |           |
| **Procedural variables** |             |                             |           |           |
| Valve malpositioning| 4 (2.0)     | 5 (2.8)                     | 17 (8.4)  | 0.004*b,c |
| Major of life-threatening bleeding | 13 (6.7) | 11 (6.3) | 41 (20.2) | < 0.001*b,c |
| Major vascular complication | 7 (3.6) | 7 (4.0) | 21 (10.5) | 0.006*b,c |
| **30-day outcomes** |             |                             |           |           |
| All-cause death     | 4 (2.0)     | 2 (1.2)                     | 26 (13.0) | < 0.001*b,c |
| Cardiovascular death | 3 (1.5)     | 1 (0.6)                     | 22 (10.6) | < 0.001*b,c |
| All stroke/TIA      | 5 (2.6)     | 6 (3.4)                     | 11 (5.6)  | 0.28      |
| Myocardial infarction | -          | -                           | 1 (0.5)   | 0.39      |
| New pacemaker       | 38 (19.5)   | 41 (23.3)                   | 48 (23.5) | 0.56      |
| New persistent LBBB | 51 (25.9)   | 40 (22.6)                   | 63 (31.1) | 0.15      |
| **1-year outcomes** |             |                             |           |           |
| All-cause death     | 30 (15.4)   | 17 (9.5)                    | 59 (29.3) | < 0.001*b,c |
| Cardiovascular death | 12 (6.0)    | 8 (4.5)                     | 43 (21.0) | < 0.001*b,c |
| All stroke/TIA      | 5 (2.6)     | 6 (3.4)                     | 10 (5.6)  | 0.21      |
| Myocardial infarction | 2 (0.8)    | -                           | 4 (1.8)   | 0.16      |
| New pacemaker       | 45 (23.0)   | 48 (27.4)                   | 51 (25.2) | 0.12      |
| New persistent LBBB | 52 (26.5)   | 41 (23.2)                   | 67 (32.9) | 0.12      |

* Represents significant statistical difference (P < 0.05) between TIRF, stable and AKI groups.

*b Significant difference (P < 0.05) between stable and AKI groups.

*c Significant difference (P < 0.05) between TIRFI and AKI groups.

Values are n (%).

Abbreviations: AKI, acute kidney injury; LBBB, left bundle branch block; TIA, transient ischemic attack; TIRFI, TAVR induced renal function improvement.

https://doi.org/10.1371/journal.pone.0251066.t002

CI, 1.06–4.07; P = 0.034) and higher baseline eGFR (HR: 1.01; 95% CI, 1.00–1.02; P = 0.053). The multivariable analysis of TIRFI and AKI including the procedure complications after TAVR in the model are shown in S2 and S3 Tables.

**Predictors of 1-year all-cause mortality**

Univariable and multivariable predictors of 1-year all-cause mortality are shown in Table 5. The presence of AKI was associated with an increase in 1-year all-cause mortality (HR: 3.42; 95% CI, 1.87–6.23; P < 0.001), as well as chronic obstructive pulmonary disease (HR: 1.72; 95% CI, 1.06–2.79; P = 0.028), baseline eGFR (HR 0.72; 95% CI, 0.61–0.86. P < 0.001) and stroke/transient ischemic attack (HR: 3.08; 95% CI, 1.74–5.44; P < 0.001).

**Discussion**

The main findings of the present study can be summarized as: (1) CKD was extremely prevalent among our population, corresponding to 70% of the patients; (2) TIRFI was frequently found after TAVR; (3) predictors of TIRFI were the absence of coronary artery disease and lower eGFR at baseline; (4) patients with AKI after TAVR had higher all-cause mortality and cardiovascular death at 30 days and 1 year; (5) there was no differences comparing 30-day and 1-year outcomes between TIRFI and stable renal function groups.

Patients with severe AS often have multiple comorbidities, and impaired renal function is associated with poor outcomes with surgical aortic valve replacement [21] and TAVR
Beyond that, the high proportion of CKD among these patients, ranging from 52% to 72% in previous large studies \cite{10,11,21} reflects the impact of these comorbidities. In our study, CKD was present in 577 (70%) of the patients from the Brazilian TAVR Registry, with an average age of 80 years and high-surgical risk according STS score.

An interesting point of our study is that TIRFI occurred similarly compared with those with AKI or stable renal function (34.1% vs. 35.2% vs. 30.7%, respectively), despite all the adverse procedural features, such as the use of contrast media, atherosclerotic particles renal embolization during catheter passage through the aorta and deployment of the valve prosthesis \cite{23}, and also the occurrence of low cardiac output during rapid ventricle pacing for balloon expandable prosthesis deployment or pre- or post-dilation of the aortic valve, which was associated with acute kidney injury and short- and long-term mortality if multiple ($\geq$ 3 episodes) or prolonged rapid ventricular pacing duration ($\geq$ 36 seconds) are performed \cite{24}.

Attempting to determine the predictors of TIRFI, we found that the absence of coronary artery disease and lower eGFR were independent predictors for renal function recovery after TAVR. Regarding to eGFR as a predictor of TIRFI, the lower the eGFR, the greater is the
chance of improvement in renal function. It can suggest that improvement in renal function is primarily due to the hemodynamics effects after TAVR procedure to relief aortic stenosis, increasing the cardiac output and leading to a better renal perfusion, suggesting that a mechanism of type 2 cardiorenal syndrome may be involved [25]. In the present analysis, there was no difference between the 3 groups related to contrast volume, use of diuretics and other variables that may contribute to deterioration of renal function. Importantly, the baseline eGFR was slightly lower among patients in the TIRFI group when compared with the AKI group, corroborating for the hypothesis that low cardiac output may be the main mechanism of impaired renal function at baseline in these population and explain why the presence of lower eGFR was found as an independent predictor of TIRFI. Also, patients without coronary artery

| Variable                          | Univariable Analysis | Multivariable Analysis |
|----------------------------------|----------------------|------------------------|
|                                  | OR (95% CI)          | P value                | OR (95% CI)          | P value |
| Age, years                       | 0.98 (0.95–1.00)     | 0.13                   | -                    | -       |
| Male sex                         | 0.84 (0.59–1.19)     | 0.32                   | -                    | -       |
| NYHA class III/IV                | 1.11 (0.69–1.76)     | 0.67                   | -                    | -       |
| Diabetes                         | 0.76 (0.52–1.11)     | 0.15                   | -                    | -       |
| Hypertension                     | 1.09 (0.74–1.63)     | 0.65                   | -                    | -       |
| COPD                             | 1.01 (0.65–1.56)     | 0.98                   | -                    | -       |
| Pulmonary hypertension           | 0.77 (0.51–1.16)     | 0.20                   | -                    | -       |
| CAD                              | 0.73 (0.51–1.04)     | 0.077                  | 0.69 (0.48–0.98)     | 0.039   |
| Peripheral vascular disease      | 1.13 (0.72–1.78)     | 0.60                   | -                    | -       |
| Previous CABG                    | 0.96 (0.62–1.46)     | 0.83                   | -                    | -       |
| STS score, %                     | 1.00 (0.98–1.03)     | 0.45                   | -                    | -       |
| eGFR, mL/min/1.73m²              | 0.98 (0.96–0.99)     | 0.014                  | 0.98 (0.97–1.00)     | 0.008   |
| Diuretics                        | 1.15 (0.80–1.64)     | 0.46                   | -                    | -       |
| ACE inhibitors or ARB            | 1.27 (0.90–1.79)     | 0.18                   | -                    | -       |
| Beta-blockers                    | 1.06 (0.75–1.51)     | 0.73                   | -                    | -       |
| Statin                           | 0.96 (0.68–1.37)     | 0.83                   | -                    | -       |
| LVEF, %                          | 0.99 (0.98–1.00)     | 0.45                   | -                    | -       |
| Mean transaortic gradient, mmHg   | 1.00 (0.99–1.02)     | 0.10                   | -                    | -       |
| AVA, cm²                         | 1.68 (0.64–4.38)     | 0.28                   | -                    | -       |
| Contrast media volume, mL        | 1.00 (0.99–1.00)     | 0.71                   | -                    | -       |
| Procedure access (except Transfemoral) | 0.58 (0.27–1.25)     | 0.16                   | -                    | -       |
| Prosthetic valve type            | -                    | 0.55                   | -                    | -       |
| Corevalve                        | 1.00                 | -                      | -                    | -       |
| Sapien XT                        | 1.00 (0.67–1.51)     | -                      | -                    | -       |
| Inovare prosthesis               | 0.54 (0.18–1.68)     | -                      | -                    | -       |
| Period of TAVR procedure         | 0.25                 | -                      | -                    | -       |
| T1 (2008–2010)                   | -                    | -                      | -                    | -       |
| T2 (2011–2013)                   | 0.87 (0.54–1.38)     | -                      | -                    | -       |
| T3 (2014–2015)                   | 1.24 (0.72–2.14)     | -                      | -                    | -       |

95% CI, 95% confidence interval.

Abbreviations: ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AVA, aortic valve area; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OR, odds ratio; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TIRFI, TAVR induced renal function improvement.

https://doi.org/10.1371/journal.pone.0251066.t003
The presence of hypertension and higher age were associated with AKI, and the endothelial dysfunction added to the occurrence of low cardiac output during the procedure could be more harmful for this population. Furthermore, the use of non-transfemoral access sites was associated with AKI after TAVR, as well as AKI group had also more procedure complications such as valve malpositioning, major or life-threatening bleeding and major vascular complication. Also, the higher eGFR at baseline, the greater is the chance of developing AKI after TAVR. This finding was probably related simply to the percentage variation of eGFR in a

Table 4. Predictors of AKI after TAVR procedure.

| Variable | Univariable Analysis | Multivariable Analysis |
|----------|----------------------|------------------------|
|          | OR (95% CI)         | P value | OR (95% CI)         | P value |
| Age, year | 1.02 (0.99–1.05)  | 0.06 | 1.03 (1.00–1.05)  | 0.033 |
| Male sex  | 0.83 (0.59–1.17)  | 0.29 | - | - |
| NYHA class III/IV | 0.99 (0.63–1.56) | 0.95 | - | - |
| Diabetes | 0.17 (0.82–1.69)  | 0.38 | - | - |
| Hypertension | 1.71 (1.13–2.59)  | 0.011 | 1.69 (1.11–2.57)  | 0.014 |
| COPD | 0.90 (0.58–1.40)  | 0.65 | - | - |
| Pulmonary hypertension | 0.94 (0.63–1.40)  | 0.75 | - | - |
| CAD | 0.99 (0.69–1.40)  | 0.93 | - | - |
| Peripheral vascular disease | 1.07 (0.68–1.69)  | 0.77 | - | - |
| Previous CABG | 0.74 (0.48–1.15)  | 0.18 | - | - |
| STS score, % | 1.00 (0.97–1.02)  | 0.98 | - | - |
| eGFR, mL/min/1.73m² | 1.01 (0.99–1.02)  | 0.008 | 1.01 (1.00–1.02)  | 0.053 |
| Diuretics | 1.15 (0.80–1.64)  | 0.44 | - | - |
| ACE inhibitors or ARB | 1.11 (0.79–1.57)  | 0.54 | - | - |
| Beta-blockers | 0.93 (0.65–1.34)  | 0.66 | - | - |
| Statin | 1.22 (0.86–1.74)  | 0.26 | - | - |
| LVEF, % | 1.00 (0.99–1.01)  | 0.28 | - | - |
| Mean transaortic gradient, mmHg | 1.00 (0.99–1.01)  | 0.97 | - | - |
| AVA, cm² | 0.71 (0.26–1.87)  | 0.49 | - | - |
| Contrast media volume, mL | 0.99 (0.99–1.00)  | 0.60 | - | - |
| Non-transfemoral access | 0.93 (1.00–3.73)  | 0.048 | 2.07 (1.06–4.07)  | 0.034 |
| Prosthetic valve type | - | 0.62 | - | - |
| Corevalve | 1.00 | - | - | - |
| Sapien XT | 0.90 (0.60–1.36)  | - | - | - |
| Inovare prosthesis | 1.46 (0.56–3.77)  | - | - | - |
| Period of TAVR procedure | - | 0.23 | - | - |
| T1 (2008–2010) | 1.00 | - | - | - |
| T2 (2011–2013) | 0.73 (0.47–1.15)  | - | - | - |
| T3 (2014–2015) | 0.63 (0.36–1.08)  | - | - | - |

95% CI, 95% confidence interval.

Abbreviations: ACE indicates angiotensin-converting enzyme; AKI, acute kidney injury; ARB, angiotensin receptor blocker; AVA, aortic valve area; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OR, odds ratio; STS, Society of Thoracic Surgeons. TAVR, transcatheter aortic valve replacement.

https://doi.org/10.1371/journal.pone.0251066.t004

Disease may have less peripheral artery disease incidence and lower rates of atherosclerotic emboli during the TAVR procedure, and that may partially explain the association with TIRFI.
## Table 5. Multivariable predictors of 1-year all-cause mortality.

| Variable                          | Univariable Analysis | Multivariable Analysis |
|-----------------------------------|----------------------|------------------------|
|                                   | Hazard Ratio (95% CI) | P value                | Hazard Ratio (95% CI) | P value |
| Age, years                        | 1.05 (0.90–1.22)     | 0.50                   | -                     | -       |
| Male sex                          | 0.77 (0.51–1.15)     | 0.21                   | -                     | -       |
| NYHA class III/IV                 | 2.16 (1.04–4.45)     | 0.038                  | 1.74 (0.83–3.63)      | 0.14    |
| Diabetes                          | 1.46 (0.97–2.22)     | 0.07                   | -                     | -       |
| Hypertension                      | 1.45 (0.88–2.41)     | 0.14                   | -                     | -       |
| COPD                              | 2.14 (1.38–3.32)     | 0.001                  | 1.72 (1.06–2.79)      | 0.028   |
| Pulmonary hypertension            | 1.69 (1.09–2.60)     | 0.017                  | 1.36 (0.86–2.16)      | 0.18    |
| CAD                               | 1.30 (0.85–1.99)     | 0.23                   | -                     | -       |
| Peripheral vascular disease       | 1.89 (1.18–3.04)     | 0.008                  | 1.58 (0.92–2.69)      | 0.09    |
| Previous CABG                     | 1.07 (0.65–1.76)     | 0.78                   | -                     | -       |
| STS score, %                      | 1.04 (1.02–1.06)     | 0.001                  | -                     | -       |
| Baseline eGFR, mL/min/1.73m**     | 0.69 (0.59–0.81)     | < 0.001                | 0.73 (0.61–0.86)      | < 0.001 |
| Baseline eGFR < 30 mL/min/1.73m²  | 2.02 (1.33–3.09)     | 0.001                  | -                     | -       |
| Diuretics                         | 1.46 (0.93–2.30)     | 0.09                   | -                     | -       |
| ACE inhibitors or ARB             | 0.80 (0.54–1.21)     | 0.30                   | -                     | -       |
| Beta-blockers                     | 0.79 (0.50–1.19)     | 0.25                   | -                     | -       |
| Statin                            | 0.97 (0.64–1.48)     | 0.91                   | -                     | -       |
| LVEF, %**                         | 0.92 (0.81–1.37)     | 0.18                   | -                     | -       |
| Mean transaortic gradient, mmHg*  | 0.94 (0.82–1.07)     | 0.34                   | -                     | -       |
| AVA, cm²                          | 0.51 (0.15–1.73)     | 0.28                   | -                     | -       |
| Contrast media volume, mL         | 1.09 (0.87–1.37)     | 0.44                   | -                     | -       |
| Procedure access (except Transfemoral) | 2.34 (1.25–4.39)  | 0.008                  | 1.29 (0.53–3.17)      | 0.57    |
| Sapien XT prosthesis              | 0.76 (0.44–1.31)     | 0.32                   | -                     | -       |
| Inovare prosthesis                | 2.55 (1.03–6.34)     | 0.043                  | -                     | -       |
| Myocardial infarction             | 4.47 (1.09–18.09)    | 0.037                  | -                     | -       |
| Stroke/TIA                        | 3.96 (2.34–6.71)     | < 0.001                | 3.08 (1.74–5.44)      | < 0.001 |
| Major or life-threatening bleeding | 1.72 (0.89–3.32)    | 0.10                   | -                     | -       |
| Major vascular complication       | 1.80 (1.03–3.13)     | 0.037                  | 1.25 (0.69–2.25)      | 0.45    |
| New LBBB                          | 1.03 (0.66–1.61)     | 0.89                   | -                     | -       |
| AV block                          | 0.85 (0.52–1.38)     | 0.51                   | -                     | -       |
| Valve malpositioning              | 4.35 (2.31–8.18)     | < 0.001                | 1.94 (0.92–4.07)      | 0.08    |
| New pacemaker                     | 0.88 (0.53–1.38)     | 0.38                   | -                     | -       |
| TIRFI                             | 1.40 (0.84–3.15)     | 0.14                   | 1.45 (0.75–2.83)      | 0.27    |
| AKI                               | 3.82 (2.12–6.88)     | < 0.001                | 3.42 (1.87–6.23)      | < 0.001 |

95% CI, 95% confidence interval.

Abbreviations: ACE indicates angiotensin-converting enzyme; AKI, acute kidney injury; ARB, angiotensin receptor blocker; AV, atriocentric valve; AVA, aortic valve area; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack; TIRFI, TAVR induced renal function improvement.

* For each increase of 5 units in age.
** For each increase of 10 units in baseline eGFR, LVEF or mean transaortic gradient.
*** For each increase of 100 units in contrast media volume.

https://doi.org/10.1371/journal.pone.0251066.1005
high-risk population with multiple comorbidities, since the results of the statistical analysis were borderline.

According to previous studies, AKI was associated with poor outcomes, including higher 1-year all-cause and cardiovascular mortality rates [9, 16, 26]. However, our study did not show association between TIRFI and lower 30-days and 1-year all-cause mortality or other outcomes when compared with stable renal function group. Our results also sustain the findings from the subanalysis of Partner 1 which included a similar population and showed no reduction in mortality rates and other outcomes in the TIRFI group [9].

A recent single-center prospective study showed that patients who had TIRFI after TAVR may also have better 30-day and 2-year outcomes, independently of the baseline kidney function [16]. The reason for discordance of our findings with this recent study could be in part because our study population surgical risk was slightly higher using the STS score, which may justify an increase in mortality even in the stable renal function and TIRFI groups.

**Limitations**

This is a prospective observational multicenter study using the Brazilian TAVR Registry and there are several inherent limitations. First, data was self-reported by each center and on-site source document verification was randomly performed in only 20% of cases. Registries studies usually do not perform source document verification, and therefore, we consider that 20% of random verification is a representative sample to validity of the data. Besides that, there is no data about measure of urine output, pre- and post-hydration strategies and proteinuria levels that might be important for AKI definition. Since there is no definition of TIRFI, we arbitrary used variation in eGFR between baseline and at discharge after TAVR of 10% for both TIRFI and AKI criteria. As most of the patients had high-surgical risk using STS score, we could not extrapolate our results for intermediate- and low-surgical risk patients. Also, despite coronary angiography are usually performed before admission for TAVR, as a routine, for evaluation of concomitant coronary artery disease in Brazilian centers which included patients in the Brazilian TAVR Registry, information on how many patients had coronary angiography and percutaneous coronary intervention during the admission for TAVR was not available. Finally, we had around 27% loss of follow-up at 1 year. However, the median follow-up of the patients included in the present study was 385 [162–742] days, and therefore, we have chosen to assess the outcomes at 1 year.

**Conclusion**

In our study, TIRFI was frequently found in patients with prior impaired renal function and promoted lower mortality when compared with patients with AKI. The absence of coronary artery disease and lower eGFR at baseline were independent predictors of TIRFI.

**Supporting information**

S1 Table. Baseline and procedural characteristics of patients with loss of follow-up versus patients with complete 1-year follow-up.

S2 Table. Predictors of TIRFI after TAVR procedure (including outcomes).

S3 Table. Predictors of AKI after TAVR procedure (including outcomes).
Acknowledgments
The authors acknowledge the expert work of Rogério R. Prado for the statistical support.

Author Contributions
Conceptualization: Michel V. Lemes da Silva, Antonio C. B. Nunes Filho, Vitor E. E. Rosa, Adriano Caixeta, Pedro A. Lemos Neto, Henrique B. Ribeiro, Breno O. Almeida, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, Roney O. Sampaio, Paulo Caramori, Rogério Sarmento-Leite, Flávio Tarasoutchi, Marcelo Franken, Fábio S. de Brito, Jr.

Data curation: Adriano Caixeta, Pedro A. Lemos Neto, Henrique B. Ribeiro, Breno O. Almeida, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, José A. Mangione, Paulo Caramori, Rogério Sarmento-Leite, Fábio S. de Brito, Jr.

Formal analysis: Michel V. Lemes da Silva, Antonio C. B. Nunes Filho, Vitor E. E. Rosa, Adriano Caixeta, Pedro A. Lemos Neto, Henrique B. Ribeiro, Carlos M. Campos, Roney O. Sampaio, Flávio Tarasoutchi, Marcelo Franken, Fábio S. de Brito, Jr.

Funding acquisition: Adriano Caixeta, Pedro A. Lemos Neto, Henrique B. Ribeiro, Breno O. Almeida, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, José A. Mangione, Paulo Caramori, Fábio S. de Brito, Jr.

Investigation: Adriano Caixeta, Pedro A. Lemos Neto, Henrique B. Ribeiro, Breno O. Almeida, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, José A. Mangione, Paulo Caramori, Rogério Sarmento-Leite, Fábio S. de Brito, Jr.

Methodology: Michel V. Lemes da Silva, Antonio C. B. Nunes Filho, Vitor E. E. Rosa, Pedro A. Lemos Neto, Henrique B. Ribeiro, Carlos M. Campos, Alexandre A. C. Abizaid, Roney O. Sampaio, Paulo Caramori, Rogério Sarmento-Leite, Fábio S. de Brito, Jr.

Project administration: Michel V. Lemes da Silva, Antonio C. B. Nunes Filho, Adriano Caixeta, Henrique B. Ribeiro, Breno O. Almeida, José Mariani, Jr, Alexandre A. C. Abizaid, José A. Mangione, Fábio S. de Brito, Jr.

Resources: Adriano Caixeta, Pedro A. Lemos Neto, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, José A. Mangione, Paulo Caramori, Rogério Sarmento-Leite, Fábio S. de Brito, Jr.

Software: Alexandre A. C. Abizaid, Fábio S. de Brito, Jr.

Supervision: Antonio C. B. Nunes Filho, Vitor E. E. Rosa, Fábio S. de Brito, Jr.

Validation: Adriano Caixeta, Pedro A. Lemos Neto, Henrique B. Ribeiro, Breno O. Almeida, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, Roney O. Sampaio, Paulo Caramori, Rogério Sarmento-Leite, Flávio Tarasoutchi, Marcelo Franken, Fábio S. de Brito, Jr.

Visualization: Michel V. Lemes da Silva, Antonio C. B. Nunes Filho, Adriano Caixeta, Henrique B. Ribeiro, José Mariani, Jr, Carlos M. Campos, Alexandre A. C. Abizaid, José A. Mangione, Roney O. Sampaio, Paulo Caramori, Rogério Sarmento-Leite, Flávio Tarasoutchi, Marcelo Franken, Fábio S. de Brito, Jr.
References

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. New England Journal of Medicine 2010; 363(17):1597–607.

2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. New England Journal of Medicine 2011; 364(23):2187–98. https://doi.org/10.1056/NEJMoa1103510 PMID: 21639811

3. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. New England Journal of Medicine 2014; 370(19):1790–98.

4. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. Journal of the American College of Cardiology 2014; 63(19):1972–81. https://doi.org/10.1016/j.jacc.2014.02.556 PMID: 24657695

5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. New England Journal of Medicine 2016; 374(17):1609–20.

6. Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. The Lancet 2016; 387(10034):2218–25. https://doi.org/10.1016/S0140-6736(16)30073-3 PMID: 27053442

7. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New England Journal of Medicine 2019; 380(18):1695–705.

8. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. New England Journal of Medicine 2019; 380(18):1706–15. https://doi.org/10.1056/NEJMoa1816885 PMID: 30883053

9. Beohar N, Doshi D, Thourani V, et al. Association of transcatheter aortic valve replacement with 30-day renal function and 1-year outcomes among patients presenting with compromised baseline renal function: experience from the PARTNER 1 Trial and Registry. JAMA cardiology 2017; 2(7):742–49. https://doi.org/10.1001/jamacardio.2017.1220 PMID: 28467527

10. Ferro CJ, Chue CD, de Belder MA, et al. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart 2015; 101(7):546–52. https://doi.org/10.1136/heartjnl-2014-307041 PMID: 25582121

11. Oguri A, Yamamoto M, Mouillet G, et al. Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2015; 10(9):e1–9. https://doi.org/10.4244/EIJV10I9A183 PMID: 25599700

12. Chen C, Zhao Z-G, Liao Y-B, et al. Impact of renal dysfunction on mid-term outcome after transcatheter aortic valve implantation: a systematic review and meta-analysis. PLoS One 2015; 10(3):e0119817. https://doi.org/10.1371/journal.pone.0119817 PMID: 25793780

13. Nguyen TC, Babaliaros VC, Razavi SA, et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement. The Journal of thoracic and cardiovascular surgery 2013; 146(6):1399–407. https://doi.org/10.1016/j.jtcvs.2013.07.065 PMID: 24075566

14. Dumontell N, Van Der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on short-and long-term outcomes after transcatheter aortic valve implantation: a Pooled-RotterdamAmsterdam-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. American heart journal 2013; 165(5):752–60. https://doi.org/10.1016/j.ahj.2012.12.013 PMID: 23622912

15. Faillace BL, Ribeiro HB, Campos CM, et al. Potential of transcatheter aortic valve replacement to improve post-procedure renal function. Cardiovascular Revascularization Medicine 2017; 18(7):507–11. https://doi.org/10.1016/j.carrev.2017.03.031 PMID: 29054156
16. Nijenhuis VJ, Peper J, Vorselaars VM, et al. Prognostic Value of Improved Kidney Function After Transcatheter Aortic Valve Implantation for Aortic Stenosis. The American journal of cardiology 2018; 121(10):1239–45. https://doi.org/10.1016/j.amjcard.2018.01.049 PMID: 29525062

17. Nunes Filho AC, Katz M, Campos CM, et al. Impact of acute kidney injury on short-and long-term outcomes after transcatheter aortic valve implantation. Revista Española de Cardiología (English Edition) 2019; 72(1):21–29. https://doi.org/10.1016/j.rec.2017.11.024 PMID: 29358043

18. de Brito FS Jr., Carvalho LA, Sarmento-Leite R, et al. Outcomes and predictors of mortality after transcatheter aortic valve implantation: results of the Brazilian registry. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 2015; 85(5):E153–62. https://doi.org/10.1002/ccd.25778 PMID: 25510532

19. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice 2012; 120(4):c179–c84. https://doi.org/10.1159/000339789 PMID: 22890468

20. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. European heart journal 2012; 33(19):2403–18. https://doi.org/10.1093/eurheartj/ehs255 PMID: 23026477

21. Thourani VH, Keeling WB, Sarin EL, et al. Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. The Annals of thoracic surgery 2011; 91(6):1798–807. https://doi.org/10.1016/j.athoracsur.2011.02.015 PMID: 21536247

22. Conrotto F, Salizzoni S, Andreis A, et al. Transcatheter aortic valve implantation in patients with advanced chronic kidney disease. The American journal of cardiology 2017; 119(9):1438–42. https://doi.org/10.1016/j.amjcard.2017.01.042 PMID: 28325569

23. Scherner M, Wahlers T. Acute kidney injury after transcatheter aortic valve implantation. Journal of thoracic disease 2015; 7(9):1527. https://doi.org/10.3978/j.issn.2072-1439.2015.06.14 PMID: 26543598

24. Fefer P, Bogdan A, Grossman Y, et al. Impact of rapid ventricular pacing on outcome after transcatheter aortic valve replacement. Journal of the American Heart Association 2018; 7(14):e009038. https://doi.org/10.1161/JAHA.118.009038 PMID: 29987119

25. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. European heart journal 2010; 31(6):703–11. https://doi.org/10.1093/eurheartj/ehp507 PMID: 20037146

26. Gargiulo G, Sannino A, Capodanno D, et al. Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. Catheterization and Cardiovascular Interventions 2015; 86(3):518–27. https://doi.org/10.1002/ccd.25867 PMID: 25641565